Differentiating Gene Therapies through Regulatory Elements

Salvador Rico, chief medical officer of Encoded Therapeutics, discusses the company’s lead program in Dravet syndrome, its efforts to develop gene therapies with optimized regulatory elements to target specific organs, and why he believes its approach is a point of differentiation for the company.